Takeda has received approval from the US Food and Drug Administration (FDA) for subcutaneous (SC) administration of Entyvio (vedolizumab) to treat moderately to severely active ulcerative colitis (UC) in adults.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,